APVO - Company ID 0001671584
The table below shows Aptevo Therapeutics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $3.11M | $12.29M | $4.31M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $14.54M | $14.38M | $17.11M | $17.88M | $18.99M | $17.85M |
| SG&A |
Aptevo Therapeutics Inc. reported annual revenue of $3.11M for fiscal year 2022. That is down 74.7% from $12.29M in fiscal 2021. Over the 8 fiscal years shown, annual revenue declined from $33.60M (FY 2015) to $3.11M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.77M |
| $10.22M |
| $11.77M |
| $13.87M |
| $14.70M |
| $13.95M |
| Operating income | -$26.31M | -$24.60M | -$28.88M | -$28.64M | -$21.40M | -$27.49M |
| Income tax | $0.00 | - | - | - | - | - |
| Net income | -$25.97M | -$24.13M | -$17.41M | $8.03M | -$28.46M | -$17.75M |
| EPS (diluted) | -$87.27 | -$31.46K | -$2.32K | $1.57 | -$6.07 | - |